Clovis Oncology (CLVS) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update
August 8, 2016 4:05 PM EDTRucaparib NDA submission completed in late June for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors FDA decision on filing and determination of PDUFA date is anticipated in late August Rucaparib MAA submission on track for Q4 2016 Rucaparib NDA dataset accepted for an oral presentation at ESMO 2016 Congress in October Clovis preparing for potential U.S. commercial launch of rucaparib ARIEL3 pivotal rucaparib maintenance study enrollment completed; data now expected in Q4... More
